MedTrace Logo

A Study on Molecular Genetics of Drug Responsiveness in Essential Hypertension

NCT03276598 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 233

Last updated 2017-09-11

No results posted yet for this study

Summary

Blood pressure variation and the risk of essential hypertension have an important genetic component. In most cases susceptibility to essential hypertension is likely determined by the action of more than one gene.

The identification of genes causing susceptibility to hypertension is important, since it would give new tools for the diagnosis and enable better etiological classification and specific treatment of the disease.

The innovation of this study is to use the response to antihypertensive therapy as an intermediate phenotype.

In the study, each subject uses one of four antihypertensive drugs, each as a monotherapy in a rotational fashion, for 28 days in a randomized order. The antihypertensive drugs to be tested include a thiazide diuretic, a beta-adrenergic antagonist, an angiotensin-II receptor antagonist and a calcium channel blocker. The drugs that are selected for the study are "typical" representatives of their groups and long-acting, and the dosages are sufficient but well tolerable.

Conditions

Interventions

DRUG

Amlodipine

Treatment for four weeks. Dose: 5 mg o.d.

DRUG

Bisoprolol

Treatment for four weeks. Dose: 5 mg o.d.

DRUG

Hydrochlorothiazide

Treatment for four weeks. Dose: 25 mg o.d.

DRUG

Losartan

Treatment for four weeks. Dose: 50 mg o.d.

DRUG

Placebo

Treatment for four weeks. Dose: 1 tablet per day.

Sponsors & Collaborators

  • Helsinki University Central Hospital

    lead OTHER

Principal Investigators

  • Kimmo K Kontula, Professor · Helsinki University Central Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
35 Years
Max Age
59 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-11-25
Primary Completion
2004-04-01
Completion
2004-04-01

Countries

  • Finland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03276598 on ClinicalTrials.gov